{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:41Z","timestamp":1760120261725,"version":"3.37.3"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Vitro Cell.Dev.Biol.-Animal"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11626-019-00392-x","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T13:03:41Z","timestamp":1565960621000},"page":"756-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-1756","authenticated-orcid":false,"given":"Gamze","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"392_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.21674","volume":"8","author":"AME Abdalla","year":"2018","unstructured":"Abdalla AME, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G (2018) Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics. Theranostics 8:533\u2013548","journal-title":"Theranostics"},{"key":"392_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2337\/db14-0719","volume":"64","author":"PK Aggarwal","year":"2015","unstructured":"Aggarwal PK, Veron D, Thomas DB, Siegel D, Moeckel G, Kashgarian M, Tufro A (2015) Semaphorin3A promotes advanced diabetic nephropathy. Diabetes 64:1743\u20131759","journal-title":"Diabetes"},{"key":"392_CR3","first-page":"1826","volume":"42","author":"PB Armstrong","year":"1982","unstructured":"Armstrong PB, Quigley JP, Sidebottom E (1982) Transepithelial invasion and intramesenchymal infiltration of the chick embryo chorioallantois by tumor cell lines. Cancer Res 42:1826\u20131837","journal-title":"Cancer Res"},{"key":"392_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.nano.2011.01.011","volume":"7","author":"RR Arvizo","year":"2011","unstructured":"Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P (2011) Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine 7:580\u2013587","journal-title":"Nanomedicine"},{"key":"392_CR5","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1242\/dev.125.24.5043","volume":"125","author":"D Bagnard","year":"1998","unstructured":"Bagnard D, Lohrum M, Uziel D, Puschel A, Bolz J (1998) Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development 125:5043\u20135053","journal-title":"Development"},{"key":"392_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/383525a0","volume":"383","author":"O Behar","year":"1996","unstructured":"Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC (1996) Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383:525\u2013528","journal-title":"Nature"},{"key":"392_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1472-8206.2010.00814.x","volume":"25","author":"SV Bhadada","year":"2011","unstructured":"Bhadada SV, Goyal BR, Patel MM (2011) Angiogenic targets for potential disorders. Fundam Clin Pharmacol 25:29\u201347","journal-title":"Fundam Clin Pharmacol"},{"key":"392_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.addr.2008.03.013","volume":"60","author":"R Bhattacharya","year":"2008","unstructured":"Bhattacharya R, Mukherjee P (2008) Biological properties of \u201cnaked\u201d metal nanoparticles. Adv Drug Deliv Rev 60:1289\u20131306","journal-title":"Adv Drug Deliv Rev"},{"key":"392_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1172\/JCI21378","volume":"114","author":"DR Bielenberg","year":"2004","unstructured":"Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, Klagsbrun M (2004) Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114:1260\u20131271","journal-title":"J Clin Invest"},{"key":"392_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ajpath.2012.04.013","volume":"181","author":"DR Bielenberg","year":"2012","unstructured":"Bielenberg DR, Seth A, Shimizu A, Pelton K, Cristofaro V, Ramachandran A, Zwaans BMM, Chen C, Krishnan R, Seth M, Huang L, Takashima S, Klagsbrun M, Sullivan MP, Adam RM (2012) Increased smooth muscle contractility in mice deficient for neuropilin 2. Am J Pathol 181:548\u2013559","journal-title":"Am J Pathol"},{"key":"392_CR11","doi-asserted-by":"publisher","first-page":"re4","DOI":"10.1126\/stke.2002.128.re4","volume":"2002","author":"G Bismuth","year":"2002","unstructured":"Bismuth G, Boumsell L (2002) Controlling the immune system through semaphorins. Sci STKE 2002:re4","journal-title":"Sci STKE"},{"key":"392_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1084\/jem.176.5.1375","volume":"176","author":"LF Brown","year":"1992","unstructured":"Brown LF, Yeo K, Berse B, Yeo T-K, Senger DR, Dvorak HF, Van De Water L (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375\u20131379","journal-title":"J Exp Med"},{"key":"392_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653\u2013660","journal-title":"Nat Med"},{"key":"392_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-642-59953-8_7","volume-title":"Vascular growth factors and angiogenesis","author":"P Carmeliet","year":"1999","unstructured":"Carmeliet P, Collen D (1999) Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. In: Claesson-Welsh L (ed) Vascular growth factors and angiogenesis. Springer, Berlin Heidelberg, Berlin, Heidelberg, pp 133\u2013158"},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s00018-006-6254-9","volume":"63","author":"S C\u00e9be Suarez","year":"2006","unstructured":"C\u00e9be Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K (2006) A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 63:2067\u20132077","journal-title":"Cell Mol Life Sci"},{"key":"392_CR16","first-page":"1238","volume":"58","author":"CR Christensen","year":"1998","unstructured":"Christensen CR, Klingelh\u00f6fer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E (1998) Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res 58:1238\u20131244","journal-title":"Cancer Res"},{"key":"392_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0002-9440(10)64309-X","volume":"162","author":"HF Dvorak","year":"2003","unstructured":"Dvorak HF (2003) How tumors make bad blood vessels and stroma. Am J Pathol 162:1747\u20131757","journal-title":"Am J Pathol"},{"key":"392_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000088479","volume":"69","author":"N Ferrara","year":"2005","unstructured":"Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69:11\u201316","journal-title":"Oncology"},{"key":"392_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"392_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0065-230X(08)60058-5","volume":"19","author":"J Folkman","year":"1974","unstructured":"Folkman J (1974) Tumor angiogenesis. Adv Cancer Res 19:331\u2013358","journal-title":"Adv Cancer Res"},{"key":"392_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4\u20136","journal-title":"J Natl Cancer Inst"},{"key":"392_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/339058a0","volume":"339","author":"J Folkman","year":"1989","unstructured":"Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58\u201361","journal-title":"Nature"},{"key":"392_CR23","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/jcp.25243","volume":"231","author":"D Frezzetti","year":"2016","unstructured":"Frezzetti D, Gallo M, Roma C, D'Alessio A, Maiello MR, Bevilacqua S, Normanno N, De Luca A (2016) Vascular endothelial growth factor a regulates the secretion of different angiogenic factors in lung cancer cells. J Cell Physiol 231:1514\u20131521","journal-title":"J Cell Physiol"},{"key":"392_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0092-8674(00)80766-7","volume":"97","author":"C Goodman","year":"1999","unstructured":"Goodman C, Kolodkin A, Luo Y, P\u00fcschel A, Raper J (1999) Unified nomenclature for the semaphorins\/collapsins. Cell 97:551\u2013552","journal-title":"Cell"},{"key":"392_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69:25\u201333","journal-title":"Oncology"},{"key":"392_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI0215467","volume":"109","author":"Y Goshima","year":"2002","unstructured":"Goshima Y, Ito T, Sasaki Y, Nakamura F (2002) Semaphorins as signals for cell repulsion and invasion. J Clin Invest 109:993\u2013998","journal-title":"J Clin Invest"},{"key":"392_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.yexcr.2013.02.003","volume":"319","author":"C Gu","year":"2013","unstructured":"Gu C, Giraudo E (2013) The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 319:1306\u20131316","journal-title":"Exp Cell Res"},{"key":"392_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u2013726","journal-title":"Nat Rev Cancer"},{"key":"392_CR29","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1007\/s00018-012-1019-0","volume":"69","author":"PK Hota","year":"2012","unstructured":"Hota PK, Buck M (2012) Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell Mol Life Sci 69:3765\u20133805","journal-title":"Cell Mol Life Sci"},{"key":"392_CR30","doi-asserted-by":"crossref","first-page":"51733","DOI":"10.18632\/oncotarget.10104","volume":"7","author":"Z-Q Hu","year":"2016","unstructured":"Hu Z-Q, Zhou S-L, Zhou Z-J, Luo C-B, Chen E-B, Zhan H, Wang P-C, Dai Z, Zhou J, Fan J, Huang X-W (2016) Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. Oncotarget 7:51733\u201351746","journal-title":"Oncotarget"},{"key":"392_CR31","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","volume":"33","author":"H Hurwitz","year":"2006","unstructured":"Hurwitz H, Saini S (2006) Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 33:S26\u2013S34","journal-title":"Semin Oncol"},{"key":"392_CR32","first-page":"7","volume":"19","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19:7\u201316","journal-title":"Oncology"},{"key":"392_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1134\/S0006297908070031","volume":"73","author":"AF Karamysheva","year":"2008","unstructured":"Karamysheva AF (2008) Mechanisms of angiogenesis. Biochemistry (Mosc) 73:751\u2013762","journal-title":"Biochemistry (Mosc)"},{"key":"392_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0022745","volume":"6","author":"CV Kavitha","year":"2011","unstructured":"Kavitha CV, Agarwal C, Agarwal R, Deep G (2011) Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One 6:1\u201312","journal-title":"PLoS One"},{"key":"392_CR35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/0008-5472.CAN-03-3090","volume":"64","author":"O Kessler","year":"2004","unstructured":"Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, Neufeld G (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64:1008\u20131015","journal-title":"Cancer Res"},{"key":"392_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a006593","volume":"2","author":"MW Kieran","year":"2012","unstructured":"Kieran MW, Kalluri R, Cho Y-J (2012) The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2:1\u201317","journal-title":"Cold Spring Harb Perspect Med"},{"key":"392_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0003287","volume":"3","author":"B Kigel","year":"2008","unstructured":"Kigel B, Varshavsky A, Kessler O, Neufeld G (2008) Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 3:1\u201314","journal-title":"PLoS One"},{"key":"392_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0065-2776(03)81005-2","volume":"81","author":"A Kumanogoh","year":"2003","unstructured":"Kumanogoh A, Kikutani H (2003) Roles of the semaphorin family in immune regulation. Adv Immunol 81:173\u2013198","journal-title":"Adv Immunol"},{"key":"392_CR39","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0022-5347(05)65820-X","volume":"166","author":"K Kunzi-Rapp","year":"2001","unstructured":"Kunzi-Rapp K, Genze F, K\u00fcfer R, Reich E, Hautmann RE, Gschwend JE (2001) Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. J Urol 166:1502\u20131507","journal-title":"J Urol"},{"key":"392_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1593\/neo.04721","volume":"7","author":"S Kusy","year":"2005","unstructured":"Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J (2005) Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 7:457\u2013465","journal-title":"Neoplasia"},{"key":"392_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0092-8674(91)90642-C","volume":"64","author":"LA Liotta","year":"1991","unstructured":"Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327\u2013336","journal-title":"Cell"},{"key":"392_CR42","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/19336918.2016.1261785","volume":"10","author":"LAT Meyer","year":"2016","unstructured":"Meyer LAT, Fritz J, Pierdant-Mancera M, Bagnard D (2016) Current drug design to target the Semaphorin\/Neuropilin\/Plexin complexes. Cell Adhes Migr 10:700\u2013708","journal-title":"Cell Adhes Migr"},{"key":"392_CR43","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1158\/1078-0432.CCR-04-2482","volume":"11","author":"P Mukherjee","year":"2005","unstructured":"Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S (2005) Antiangiogenic properties of gold nanoparticles. Clin Cancer Res 11:3530\u20133534","journal-title":"Clin Cancer Res"},{"key":"392_CR44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1101\/sqb.2002.67.227","volume":"67","author":"J Nagy","year":"2002","unstructured":"Nagy J, Vasile E, Feng D, Sundberg C, Brown L, Manseau E, Dvorak A, Dvorak H (2002b) VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 67:227\u2013237","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"392_CR45","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.20021244","volume":"196","author":"JA Nagy","year":"2002","unstructured":"Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF (2002a) Vascular permeability factor\/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196:1497\u20131506","journal-title":"J Exp Med"},{"key":"392_CR46","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphys.2018.01662","volume":"9","author":"H Nakayama","year":"2018","unstructured":"Nakayama H, Kusumoto C, Nakahara M, Fujiwara A, Higashiyama S (2018) Semaphorin 3F and netrin-1: the novel function as a regulator of tumor microenvironment. Front Physiol 9:1662\u20131662","journal-title":"Front Physiol"},{"key":"392_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1593\/neo.04481","volume":"7","author":"P Nasarre","year":"2005","unstructured":"Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J (2005) Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7:180\u2013189","journal-title":"Neoplasia"},{"key":"392_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/978-0-387-70956-7_10","volume-title":"Semaphorins: receptor and intracellular signaling mechanisms","author":"G Neufeld","year":"2007","unstructured":"Neufeld G, Lange T, Varshavsky A, Kessler O (2007) Semaphorin signaling in vascular and tumor biology. In: Pasterkamp RJ (ed) Semaphorins: receptor and intracellular signaling mechanisms. Springer, New York, US, pp 118\u2013131"},{"key":"392_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2741\/1569","volume":"10","author":"G Neufeld","year":"2005","unstructured":"Neufeld G, Shraga-Heled N, Lange T, Guttmann-Raviv N, Herzog Y, Kessler O (2005) Semaphorins in cancer. Front Biosci 10:751\u2013760","journal-title":"Front Biosci"},{"key":"392_CR50","first-page":"4435","volume":"49","author":"JA Plumb","year":"1989","unstructured":"Plumb JA, Milroy R, Kaye SB (1989) Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49:4435\u20134440","journal-title":"Cancer Res"},{"key":"392_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2008.05.032","volume":"273","author":"VA Potiron","year":"2009","unstructured":"Potiron VA, Roche J, Drabkin HA (2009) Semaphorins and their receptors in lung cancer. Cancer Lett 273:1\u201314","journal-title":"Cancer Lett"},{"key":"392_CR52","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1158\/0008-5472.CAN-06-3612","volume":"67","author":"VA Potiron","year":"2007","unstructured":"Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA (2007) Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 67:8708\u20138715","journal-title":"Cancer Res"},{"key":"392_CR53","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ajpath.2013.06.022","volume":"183","author":"KJ Reidy","year":"2013","unstructured":"Reidy KJ, Aggarwal PK, Jimenez JJ, Thomas DB, Veron D, Tufro A (2013) Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction. Am J Pathol 183:1156\u20131168","journal-title":"Am J Pathol"},{"key":"392_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/002215540205000108","volume":"50","author":"G Ren","year":"2002","unstructured":"Ren G, Michael LH, Entman ML, Frangogiannis NG (2002) Morphological characteristics of the microvasculature in healing myocardial infarcts. J Histochem Cytochem 50:71\u201379","journal-title":"J Histochem Cytochem"},{"key":"392_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ar.10021","volume":"264","author":"D Ribatti","year":"2001","unstructured":"Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V (2001) Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 264:317\u2013324","journal-title":"Anat Rec"},{"key":"392_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/386671a0","volume":"386","author":"W Risau","year":"1997","unstructured":"Risau W (1997) Mechanisms of angiogenesis. Nature 386:671\u2013674","journal-title":"Nature"},{"key":"392_CR57","first-page":"1289","volume":"12","author":"J Roche","year":"1996","unstructured":"Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R (1996) Distinct 3p21. 3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12:1289\u20131297","journal-title":"Oncogene"},{"key":"392_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4161\/cam.4.1.10207","volume":"4","author":"Q Schwarz","year":"2010","unstructured":"Schwarz Q, Ruhrberg C (2010) Neuropilin, you gotta let me know: should I stay or should I go? Cell Adhes Migr 4:61\u201366","journal-title":"Cell Adhes Migr"},{"key":"392_CR59","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1073\/pnas.1232173100","volume":"100","author":"TW Secomb","year":"2003","unstructured":"Secomb TW, Konerding MA, West CA, Su M, Young AJ, Mentzer SJ (2003) Microangiectasias: structural regulators of lymphocyte transmigration. Proc Natl Acad Sci U S A 100:7231\u20137234","journal-title":"Proc Natl Acad Sci U S A"},{"key":"392_CR60","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.93.9.4120","volume":"93","author":"Y Sekido","year":"1996","unstructured":"Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, Albanesi JP, Lee CC, Lerman MI, Minna JD (1996) Human semaphorins a(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A 93:4120\u20134125","journal-title":"Proc Natl Acad Sci U S A"},{"key":"392_CR61","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature01784","volume":"424","author":"G Serini","year":"2003","unstructured":"Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424:391\u2013397","journal-title":"Nature"},{"key":"392_CR62","doi-asserted-by":"publisher","first-page":"27230","DOI":"10.1074\/jbc.M804520200","volume":"283","author":"A Shimizu","year":"2008","unstructured":"Shimizu A, Mammoto A, Italiano JE Jr, Pravda E, Dudley AC, Ingber DE, Klagsbrun M (2008) ABL2\/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. J Biol Chem 283:27230\u201327238","journal-title":"J Biol Chem"},{"key":"392_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0169-328X(00)00198-4","volume":"83","author":"A Shirvan","year":"2000","unstructured":"Shirvan A, Shina R, Ziv I, Melamed E, Barzilai A (2000) Induction of neuronal apoptosis by semaphorin3A-derived peptide. Mol Brain Res 83:81\u201393","journal-title":"Mol Brain Res"},{"key":"392_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ni1553","volume":"9","author":"K Suzuki","year":"2008","unstructured":"Suzuki K, Kumanogoh A, Kikutani H (2008) Semaphorins and their receptors in immune cell interactions. Nat Immunol 9:17\u201323","journal-title":"Nat Immunol"},{"key":"392_CR65","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/sj.embor.7400114","volume":"5","author":"L Tamagnone","year":"2004","unstructured":"Tamagnone L, Comoglio PM (2004) To move or not to move? Semaphorin signalling in cell migration. EMBO Rep 5:356\u2013361","journal-title":"EMBO Rep"},{"key":"392_CR66","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/nano5031297","volume":"5","author":"G Tan","year":"2015","unstructured":"Tan G, Kantner K, Zhang Q, Soliman M, del Pino P, Parak W, Onur M, Valdeperez D, Rejman J, Pelaz B (2015) Conjugation of polymer-coated gold nanoparticles with antibodies\u2014synthesis and characterization. Nanomaterials 5:1297\u20131316","journal-title":"Nanomaterials"},{"key":"392_CR67","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11051-017-3967-7","volume":"19","author":"G Tan","year":"2017","unstructured":"Tan G, Onur MA (2017) Anti-proliferative effects of gold nanoparticles functionalized with semaphorin 3F. J Nanopart Res 19:283\u2013298","journal-title":"J Nanopart Res"},{"key":"392_CR68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5606\/tji.2013.267","volume":"1","author":"G Terzio\u011flu","year":"2013","unstructured":"Terzio\u011flu G, Keskin A\u00dc, Demirel GY (2013) Measurement methods of cell proliferation and a comparison of various commercial proliferation kits. Turk J Immunol 1:74\u201389","journal-title":"Turk J Immunol"},{"key":"392_CR69","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.1073\/pnas.231490898","volume":"98","author":"Y Tomizawa","year":"2001","unstructured":"Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD (2001) Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21. 3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 98:13954\u201313959","journal-title":"Proc Natl Acad Sci U S A"},{"key":"392_CR70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev.cellbio.22.010605.093554","volume":"23","author":"TS Tran","year":"2007","unstructured":"Tran TS, Kolodkin AL, Bharadwaj R (2007) Semaphorin regulation of cellular morphology. Annu Rev Cell Dev Biol 23:263\u2013292","journal-title":"Annu Rev Cell Dev Biol"},{"key":"392_CR71","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bjophthalmol-2011-301005","volume":"96","author":"RJ Van Geest","year":"2012","unstructured":"Van Geest RJ, Lesnik-Oberstein SY, Tan HS, Mura M, Goldschmeding R, Van Noorden CJF, Klaassen I, Schlingemann RO (2012) A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol 96:587\u2013590","journal-title":"Br J Ophthalmol"},{"key":"392_CR72","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1158\/1078-0432.CCR-10-0839","volume":"17","author":"F Wu","year":"2011","unstructured":"Wu F, Zhou Q, Yang J, Duan G-j, Ou J-j, Zhang R, Pan F, Peng Q-p, Tan H, Ping Y-f, Cui Y-h, Qian C, Yan X-c, Bian X-w (2011) Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma. Clin Cancer Res 17:2702\u20132711","journal-title":"Clin Cancer Res"},{"key":"392_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000443645","volume":"132","author":"J Xia","year":"2016","unstructured":"Xia J, Worzfeld T (2016) Semaphorins and plexins in kidney disease. Nephron 132:93\u2013100","journal-title":"Nephron"},{"key":"392_CR74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1006\/geno.1996.0074","volume":"32","author":"R-H Xiang","year":"1996","unstructured":"Xiang R-H, Hensel CH, Garcia DK, Carlson HC, Kok K, Daly MC, Kerbacher K, van den Berg A, Veldhuis P, Buys CH (1996) Isolation of the human semaphorin III\/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics 32:39\u201348","journal-title":"Genomics"},{"key":"392_CR75","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1006\/bbrc.2002.6478","volume":"291","author":"S Yamaguchi","year":"2002","unstructured":"Yamaguchi S, Iwata K, Shibuya M (2002) Soluble flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 291:554\u2013559","journal-title":"Biochem Biophys Res Commun"},{"key":"392_CR76","first-page":"1397","volume":"19","author":"W Yu","year":"2013","unstructured":"Yu W, Bai Y, Han N, Wang F, Zhao M, Huang L, Li X (2013) Inhibition of pathological retinal neovascularization by semaphorin 3A. Mol Vis 19:1397\u20131405","journal-title":"Mol Vis"}],"container-title":["In Vitro Cellular & Developmental Biology - Animal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-019-00392-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11626-019-00392-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-019-00392-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T20:23:22Z","timestamp":1664137402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11626-019-00392-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s11626-019-00392-x","relation":{},"ISSN":["1071-2690","1543-706X"],"issn-type":[{"type":"print","value":"1071-2690"},{"type":"electronic","value":"1543-706X"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}